Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Postauricular swelling with a protruding pinna suggests mastoiditis. Drowsiness, meningism, persistent severe headache, diplopia or focal neurological findings may indicate intracranial spread, sometimes without obvious mastoid signs.
Action: Arrange immediate hospital assessment, call senior ENT and paediatric or medical teams, and assess airway, breathing, circulation and neurological state. Start the appropriate severe-infection treatment promptly while arranging imaging and source-control decisions.
Synopsis
Recognise mastoid and intracranial extension of ear infection, initiate urgent hospital care and understand how imaging, intravenous antimicrobials and surgical source control work together.
The middle-ear cleft communicates with mastoid air cells, allowing acute infection to extend into the mastoid.
Clinical mastoiditis is suggested by painful postauricular inflammation and displacement of the pinna.
Mastoid fluid on a scan alone does not establish acute mastoiditis or mandate surgery.
Key red flags
Tender postauricular swelling, fluctuance, loss of the ear crease or a pinna pushed outwards suggests infection involving the mastoid or a subperiosteal collection.
Investigation priorities
01
Blood tests and microbiologyFirst step
Assess inflammatory burden and guide antimicrobial treatment safely.
Management branches
Initial hospital careStabilise and start coordinated treatment
Clinical findings suggest mastoiditis or a complication of middle-ear infection.
Arrange urgent ENT and senior paediatric or adult medical assessment, with anaesthetic or critical-care help for threatened airway or physiological instability.
Assess and treat airway, breathing and circulation, give appropriate analgesia and address dehydration using the age-appropriate acute-care pathway.
Key medicines
Intravenous co-amoxiclav for selected adult mastoiditisThe NHS Forth Valley adult hospital pathway uses co-amoxiclav 1.2 g intravenously every eight hours, adjusted for renal impairment. Its total treatment range is seven to fourteen days, with longer treatment for severe or extensive disease and an individually reviewed IV-to-oral switch.
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.